New drug aims to stop throat cancer from coming back
NCT ID NCT07303283
First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 27 times
Summary
This study tests a new drug, Becotatug vedotin, against a standard chemotherapy pill (capecitabine) to see which is better at preventing cancer from returning in people with advanced nasopharyngeal cancer. About 218 adults who have already completed standard chemoradiation will be randomly assigned to one of the two treatments. The goal is to improve the chance of staying cancer-free without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.